Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): Secondary outcomes of a phase 3, randomised controlled trial
Harry D. Bear, Gong Tang, Priya Rastogi, Charles E. Geyer, Qing Liu, André Robidoux, Luis Baez-Diaz, Adam M. Brufsky, Rita S. Mehta, Louis Fehrenbacher, James A. Young, Francis M. Senecal, Rakesh Gaur, Richard G. Margolese, Paul T. Adams, Howard M. Gross, Joseph P. Costantino, Soonmyung Paik, Sandra M. Swain, Eleftherios P. MamounasNorman Wolmark
Dive into the research topics of 'Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): Secondary outcomes of a phase 3, randomised controlled trial'. Together they form a unique fingerprint.